Defence Therapeutics Inc. Seeks to Advance Its Biopharmaceutical innovations at Biotech Showcase
Montreal, Quebec–(Newsfile Corp. – January 10, 2025)
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), a leading Canadian biopharmaceutical company, is set to participate in the Biotech ShowcaseTM conference this week during the J.P. Morgan Healthcare Conference in San Francisco. The company aims to engage with industry leaders, partners, and potential investors to strengthen its US ecosystem presence and highlight the strength of its proprietary ACCUM® technology platform.
Key Highlights from the Biotech Showcase
The Biotech Showcase is a premier investor conference dedicated to providing biotech companies with a unique platform to showcase their innovations. This year’s event will take place from January 13-16 in San Francisco as part of the J.P. Morgan Healthcare Conference, which attracts thousands of industry leaders and investors.
Our Strategy:
Our Chief Scientific Officer, Dr. Maxime Parisotto, and I are actively participating in the conference to meet with global industry leaders, potential partners, and investors. Our primary goal is to strengthen our network in the US ecosystem while demonstrating the exceptional value of the ACCUM® technology platform. This platform has transformative potential in improving ADCs and advancing targeted radiopharmaceutical therapies, which we intend to leverage for our future endeavors.
Financial Update: $300 Million Financing Round Closed
Earlier this month, Defence Therapeutics successfully raised $300 million through a highly successful equity financing round. The company utilized these proceeds to accelerate the development of its innovative ADC products and establish robust working capital for ongoing operations.
The ACCUM® Technology Platform:
The ACCUM platform represents a groundbreaking approach in targeted cancer therapy. By enabling precise delivery of therapeutic agents to specific tissues, it addresses critical challenges associated with traditional treatment methods. Our team has made significant progress in both preclinical and clinical stages, with promising Phase 1a data already demonstrating the safety and efficacy profile of our ADC candidates.
Market Impact:
This milestone not only positions Defence Therapeutics as a leader in biopharmaceutical innovation but also underscores its potential to influence the future of cancer treatment. The company’s commitment to precision medicine extends beyond oncology, with applications in infectious diseases and other therapeutic areas.
Company Overview
Founded on a mission to revolutionize targeted therapies, Defence Therapeutics has established itself as a key player in the biopharmaceutical sector. Our dedicated team of scientists, engineers, and medical experts works tirelessly to develop innovative solutions that address unmet patient needs while maintaining strict regulatory standards.
Our Vision:
We are committed to advancing precision delivery in cancer and infectious disease treatments through our ACCUM® technology platform. By combining cutting-edge science with robust development pipelines, we aim to transform the way patients receive therapy, ultimately improving outcomes and reducing side effects.
Financial Projections
The $300 million funding round has been instrumental in enabling us to expand our global footprint. With the proceeds, we plan to accelerate clinical trials for our ADC candidates, explore strategic partnerships, and strengthen our manufacturing capabilities to meet increasing demand from healthcare providers worldwide.
Future Outlook:
We are excited about the potential of the ACCUM platform to revolutionize cancer treatment while also contributing to solutions for other chronic conditions. Our team is well-positioned to capitalize on this opportunity, with a strong pipeline of candidates in various stages of development.
Commitment to Innovation
Defence Therapeutics Inc. remains dedicated to advancing its innovative biopharmaceutical platform while maintaining strict adherence to regulatory requirements and ethical standards. Our focus on collaboration with global experts ensures that we continue to push the boundaries of what’s possible in targeted therapy.
About ACCUM® Technology:
The ACCUM platform represents a paradigm shift in cancer treatment, offering precise targeting capabilities that minimize systemic toxicity while maximizing therapeutic efficacy. Our Phase 1a data already demonstrate promising safety and efficacy profiles, paving the way for further development.
Conclusion
Defence Therapeutics Inc. is poised to make significant strides in its pursuit of innovative biopharmaceutical solutions. With a robust pipeline, a cutting-edge platform, and a dedicated team, we are well on our way to transforming the future of cancer treatment. We look forward to welcoming you to the Biotech ShowcaseTM and to continuing our journey towards impactful and life-changing therapies.
This press release contains forward-looking statements concerning various aspects of Defence Therapeutics Inc.’s business, financial condition, and results of operations. These include statements regarding the company’s participation in the Biotech Showcase, its fundraising efforts, ACCUM technology platform capabilities, and future plans for its ADC products. These statements involve known or unknown risks and uncertainties that may affect future outcomes.
Cautionary Note:
The forward-looking information contained herein is based on current expectations about future events which are subject to significant risks and uncertainties. Any actual results could differ materially from those expressed or implied in this press release, including the regulatory actions, market conditions, availability of capital, and general economic factors beyond the company’s control.
Neither the Canadian Securities Exchange nor its Market Regulator accepts responsibility for ensuring the adequacy or accuracy of this release. For further details, please visit the website provided.
Source: Newsfile Corp.
View Source: https://www.newsfilecorp.com/release/236764
